FILATOV- KOPLIK SPOTS

As a result of scientific nihilism against Measles immunisation, (1954 Enders & Peebles),among certain population groups,physicians are again seeing FILATOV-KOPLIK spots. Russian aristocrat Dr NIL FILAKOV (1847-1902)post-grad.studies : Berlin,Paris,Prague and Vienna. American Dr HENRY KOPLIK (1858-1927) NY Mt Sinai Hosp(25y) post-grad studies: Berlin,Prague,Vienna.

Dr.B.DAY MBChB(Manchester) MRCP(London- Int Med.) FRCS(Eng.) FRCS(Can.) PRIVATE CAMBIE SURGICAL CENTRE Vancouver.

Dr. Brian Day 2007-2008 President - Canadian Medical Association Health Care Quotes This page contains a collection of noteable quotes relating to Canadian Health Care. "Personally, I do not see in Canada it would be a feasible thing if any Ministry organized taking over both the Health and the Disease of the entire community... even in the most favourable circumstances... there would be that absence of competition and that sense of independence... I do not believe it would be good for the profession or good for the Public." - Sir William Osler in a speech to the Medical Society of the Canadian Army Medical Corps (1918) Sir William Osler "...our noble tradition that no sick person of any age, sex, race or religion whatsoever, shall ever suffer for need of medical care on account of poverty or any other cause...should be based on our willingness to give, and should be construed as an act of our charity. It should not be exploited: nor should it be assumed as a God-given right by way of its beneficiaries. Least of all should it be a right-of-way for needy and penurious governmental and administrative bodies." - Dr. J.H MacDermot Osler lecture (1939) Dr. J.H MacDermot "There will come a time when the Ministry of Health is the only Ministry we can afford to have and we still won't be able to afford the Ministry of Health" - Dalton McGuinty, Premier of Ontario Dalton McGuinty "The evidence shows that delays in the public health care system are widespread and patients die as a result of waiting lists for public health care" - Supreme Court of Canada, June, 2005 Supreme Court of Canada "The courts have a duty to rise above political debate" - Supreme Court of Canada, June, 2005 Supreme Court of Canada "I think we have to be very careful about empowering the consumer because they will make choices that are not in their own health interest" - Jonathan Lomas, Executive Director, Canadian Health Services Research Foundation (a $100 million plus tax supported non profit agency) Jonathan Lomas "When consumers apply pressure on an industry, whether it's retailing or banking, cars or computers, it invariably produces a surge of innovation that increases productivity, reduces prices, improves quality and expands choices. The essential problem with the health care industry is that it has been shielded from consumer control - by employers, insurers and the government. As a result, costs have exploded as choices have narrowed" - Regina Herzlinger, Harvard Business Review, 2002 Regina Herzlinger "In fact, the Canadian health care system is perhaps the most rigid and oppressive (to physicians) within the free world." - David J. Dandy, Vice President, Royal College of Surgeons of England David J. Dandy "In the wake of the Supreme Court of Canada decision (Chaoulli-Zeliotis), the Canadian Medicare system is about to be redesigned. Physicians must not just sit at the table, but must position themselves at the head, where they can lead and direct the nature of that design." - Dr. Brian Day "When it comes to physicians there is a common thread that is a major barrier to solving our concerns. We are divided. The result is a divide and conquer scenario, in which we negotiate as adversaries, first with government and then with one another about our relative worth, while the "conqueror" observes and continues to rule." - Dr. Brian Day

FREE WEBINAR:IMMUNOGLOBULIN Heavy/Light Chain Assay.

The Binding Site Group Ltd Hevylite® Webinar by Key Opinion Leader and Live Q & A Session ‘The Immunoglobulin Heavy/Light Chain (Hevylite) assay for diagnosis, response evaluation, and evaluation of biological aspects of multiple myeloma’ Presented by University Professor Dr Heinz Ludwig Wilhelminenspital, Vienna, Austria Dr_Heinz_Ludwig_with_Dr_Stephen_Harding Professor Dr Heinz Ludwig with Dr Stephen Harding, Research & Development Director at Binding Site Headquarters Birmingham, UK Monday 10th March 2014 07:00PM - 08:00PM GMT Register Now OR Tuesday 11th March 2014 10:00AM - 11:00AM GMT Register Now What will you learn from this webinar? The Hevylite assay improves detection and measurement of monoclonal proteins that are: Difficult to quantify by electrophoresis At low levels How to improve monitoring of Multiple Myeloma patients with Hevylite The Hevylite ratio lets you: Assess the presence of monoclonal protein production over polyclonal protein production Identify residual disease in some cases that are negative by electrophoresis Detect relapse in some cases where electrophoresis is negative After the webinar, keep listening for a Live Question & Answer Session with Binding Site's Research & Development Director, Dr Stephen Harding, who developed the Hevylite assay. View our Disclaimer. There is no fee to attend this webinar. After registering you will receive a confirmation email containing information about joining the webinar. System Requirements PC-based attendees require: Windows® 8, 7, Vista, XP or 2003 Server Macintosh® based attendees require: Mac OS® X 10.6 or newer Mobile attendees require: iPhone®, iPad®, Android™ phone or tablet Binding Site - Committed to improving patient lives worldwide through education, collaboration & innovation

USA ENTEROVIRUS ACUTE FLACCID PARALYSIS

Enterovirus 68 is associated with respiratory illness and shares biological features with both the enteroviruses and the rhinoviruses M. Steven Oberste1, Kaija Maher1, David Schnurr2, Mary R. Flemister1, Judith C. Lovchik3, Heather Peters4, Wendy Sessions5, Carol Kirk6, Nando Chatterjee7, Susan Fuller8, J. Michael Hanauer9 and Mark A. Pallansch1 + Author Affiliations 1Respiratory and Enteric Viruses Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA 2Viral and Rickettsial Disease Laboratory, California Department of Health Services, Richmond, CA, USA 3Clinical Virology Laboratory, University of Maryland Medical System, Baltimore, MD, USA 4State of Maryland Department of Health and Mental Hygiene, Baltimore, MD, USA 5Medical Virology Laboratory, Texas Department of Health, Austin, TX, USA 6Wisconsin State Laboratory of Hygiene, University of Wisconsin-Madison, Madison, WI, USA 7Wadsworth Center, New York State Department of Health, Albany, NY, USA 8Public Health Laboratory, Minnesota Department of Health, Minneapolis, MN, USA 9Missouri State Public Health Laboratory, Department of Health and Senior Services, Jefferson City, MO, USA Correspondence M. Steven Oberste soberste@cdc.gov Received 19 December 2003. Accepted 20 May 2004. Next Section Abstract Enterovirus (EV) 68 was originally isolated in California in 1962 from four children with respiratory illness. Since that time, reports of EV68 isolation have been very uncommon. Between 1989 and 2003, 12 additional EV68 clinical isolates were identified and characterized, all of which were obtained from respiratory specimens of patients with respiratory tract illnesses. No EV68 isolates from enteric specimens have been identified from these same laboratories. These recent isolates, as well as the original California strains and human rhinovirus (HRV) 87 (recently shown to be an isolate of EV68 and distinct from the other human rhinoviruses), were compared by partial nucleotide sequencing in three genomic regions (partial sequencing of the 5′-non-translated region and 3D polymerase gene, and complete sequencing of the VP1 capsid gene). The EV68 isolates, including HRV87, were monophyletic in all three regions of the genome. EV68 isolates and HRV87 grew poorly at 37 °C relative to growth at 33 °C and their titres were reduced by incubation at pH 3·0, whereas the control enterovirus, echovirus 11, grew equally well at 33 and 37 °C and its titre was not affected by treatment at pH 3·0. Acid lability and a lower optimum growth temperature are characteristic features of the human rhinoviruses. It is concluded that EV68 is primarily an agent of respiratory disease and that it shares important biological and molecular properties with both the enteroviruses and the rhinoviruses. Previous SectionNext Section The GenBank/EMBL/DDBJ accession numbers reported in this paper are AY426486–AY426531.

CMAJ LEPROSY in MONTREAL. Hopital du Sacre-Coeur.

CMAJ Feb. 16, 2014 p.206-209, M.ALBERT & F.TREMBLAY. 60y, pale skinned, car mechanic who visited Haiti & Philippines. Treated first for a year with Steroids and methotrexate for "Rheum.arthritis". Developed rash and periph.neuropathy. SKIN BIOPSY positive for Myco.leprae.incl.positive polymerase chain reaction. Prevalence of M.leprae infection Canada 6:1,000,000. In Canada at least 210 Lepers. COMMENT At first (?francophone)neurologist diagnosed as familial "sensitivomotor" polyneuropathy (probably meant familial SENSORY-MOTOR polyneuropathy.)

CMAJ: A left-wing anti-capitalist journal.

Senior editor CMAJ Dr.K. FLEGEL MDCM (McGill) MSc wrote a whole page on the evils of naming Med. Schools after a donor. CMAJ ,Feb.18,2014 p.232. Writes in the " SALON" CMAJ section: "The house of the rising sun medical school" (whatever this means). His alma mater McGill was founded in 1811 by a Fur trader James McGill who donated his Country estate plus GBP 10,000 (equivalent to at least $2-million today). Toronto teaching hospitals depend on the large donations of philanthropists. Dr.Flegel quotes the Paul DALLA LANA (Toronto), Michael DEGROOT (Hamilton)and Seymour SCHULICH (Toronto)schools. Canuck medicine is blighted by (fiscally envious) Lefty agitators.

DENMARK: HPV VACCINE REDUCES PREVALENCE CANCER CERVIX.

Reduced risk of cervical lesions associated with HPV vaccination in Denmark Friday 21 February 2014 - 1am PST A reduced risk of cervical lesions among Danish girls and women at the population level is associated with use of a quadrivalent HPV vaccine after only six years, according to a new study published in the Journal of the National Cancer Institute. Two HPV vaccines are currently available and have proven to be highly effective against HPV16/18-associated cervical cancer. One of these vaccines, a quadrivalent vaccine, was licensed in Denmark in 2006, and it was subsequently incorporated into general childhood vaccination programs for girls free of charge and was made available to girls and women and to boys and men not covered by the program for a fee. To date, a nationwide population-based study of HPV-related cervical abnormalities in vaccinated vs unvaccinated women based on information on vaccination status at the individual level has not been reported. Susanne Krüger Kjaer, MD, and her team from Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center in Copenhagen, Denmark, and colleagues identified all girls and women born in Denmark in 1989-1999 and obtained the corresponding HPV vaccination status in 2006-2012 for each individual, as well as information on incident cases of cervical lesions among those in the cohort. Risk of cervical atypia (abnormal cervical cells) or worse (atypia+) and cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) were statistically significantly reduced among vaccinated women born between 1991 and 1994 vs unvaccinated women. Among women born between 1989 and 1990, a statistically significant reduced risk of atypia+ was observed for vaccinated vs unvaccinated women; similar results were observed for CIN2/3 but these findings did not reach statistical significance. Furthermore, no cervical lesions were reported among girls born between 1997 and 1999. The authors write, "In conclusion, our results show that vaccination with the quadrivalent HPV vaccine is already effective in reducing the risk for cervical precursor lesions at population level among young women in Denmark."